Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Bioorganic Chemistry|July 26, 2024
7-Amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines as CK1δ inhibitors: Exploring substitutions at the 2 and 5-positionsIlenia Grieco, Davide Bassani, Letizia Trevisan, et al.Bioorganic & Medicinal Chemistry|September 13, 2011
Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?Siew Lee Cheong, Anton V Dolzhenko, Silvia Paoletta, et al.Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 DeltaSara Calenda, Daniela Catarzi, Flavia Varano, et al.Chemmedchem|September 7, 2023
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell LinesStephanie Federico, Margherita Persico, Letizia Trevisan, et al.European Journal of Medicinal Chemistry|March 15, 2021
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systemsIlenia Grieco, Maicol Bissaro, Davide Benedetto Tiz, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|August 25, 2018
Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approachDelia Preti, Romeo Romagnoli, Riccardo Rondanin, et al.Molecules (Basel, Switzerland)|October 17, 2019
Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer TherapyAaron Tan, Maria V Babak, Gopalakrishnan Venkatesan, et al.Chemmedchem|December 15, 2018
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic InhibitionSara Redenti, Irene Marcovich, Teresa De Vita, et al.Plos One|January 6, 2018
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatmentYi-Ming Shao, Xiaohua Ma, Priyankar Paira, et al.Pharmaceuticals (Basel, Switzerland)|June 1, 2023
"Dual Anta-Inhibitors" of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling StudiesAndrea Spinaci, Michela Buccioni, Daniela Catarzi, et al.Pageof 10